Metastatic Renal Cell Carcinoma: Response to Treatment with Human Recombinant Erythropoietin
Authors: Jonathan Rubins
Journal: Annals of Internal Medicine (1995)

Brief Communications1 May 1995Metastatic Renal Cell Carcinoma: Response to Treatment with Human Recombinant ErythropoietinJonathan Rubins, MDJonathan Rubins, MDFrom Canandaigua Medical Group and F. F. Thompson Hospital, Canandaigua, New York.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-122-9-199505010-00005 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Approximately 18 000 cases of renal cell carcinoma occur annually in the United States, and about 80% of patients with this condition eventually develop metastatic disease [1]. The prognosis for these patients is poor: They have a median survival time of about 12 months, and 0% to 20% survive for 5 years. Chemotherapy using infusional floxuridine produces response rates of 15% to 20%, but most responses are of short duration [2]. Immunotherapy using interferon-α or interleukin-2 results in similar response rates, although durable complete responses are seen more often with interleukin-2 [3]. Most patients fail to respond to these treatments ...References1. Maldazys JF, deKernion JB. Prognostic factors in metastatic renal carcinoma. J Urol. 1986; 136:376-9. Google Scholar2. Wilkinson MJ, Frye JW, Small EJ, Venook AP, Carroll PR, Ernest ML, Stagg RJ. A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma. Cancer. 1993; 71:3601-4. Google Scholar3. Sleijfer DT, Janssen RA, Buter J, de Vries EG, Willemse PH, Mulder NH. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol. 1992; 10:1119-23. Google Scholar4. Nseyo UO, Williams PD, Murphy GP. Clinical significance of erythropoietin levels in renal carcinoma. Urology. 1986; 28:301-6. Google Scholar5. Janik JE, Sznol M, Urba WJ, Figlin R, Bukowski RM, Fyfe G, et al. Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumors. Cancer. 1993; 72:2656-9. Google Scholar6. Everson TC. Spontaneous regression of cancer. Ann N Y Acad Sci. 1964; 114:721-35. Google Scholar7. Bloom HJ. Proceedings: Hormone-induced and spontaneous regression of metastatic renal cancer. Cancer. 1973; 32:1066-71. Google Scholar Author, Article, and Disclosure InformationAuthors: Jonathan Rubins, MDAffiliations: From Canandaigua Medical Group and F. F. Thompson Hospital, Canandaigua, New York.Corresponding Author: Jonathan Rubins, MD, F.F. Thompson Hospital, 350 Parrish Street, Canandaigua, NY 14424.Acknowledgment: The author thanks Ms. Dawn Freeland for preparation of the manuscript. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byFunctional significance of erythropoietin in renal cell carcinomaThe role of erythropoietin receptor expression on tumor cellsImmuntherapie des metastasierten Nierenzellkarzinoms mit Interleukin-2, Interferon-α2a und Erythropoetin-βDas Nachsorgeprinzip beim metastasierten ProstatakarzinomErythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studiesrhEPO in anemia associated with solid tumors and chemotherapyCurrent status and future developments of rhEPO in clinical oncologyErythropoietin stimulates proliferation of human renal carcinoma cellsThe effect of human recombinant erythropoietin on the growth of a human neuroblastoma cell line 1 May 1995Volume 122, Issue 9Page: 676-677KeywordsAbdominal painAnemiaComputed axial tomographyErythropoietinHematocritLesionsPolycythemiaRenal cell carcinomaThoraxWeight loss ePublished: 15 August 2000 Issue Published: 1 May 1995 Copyright & PermissionsCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...